Arca
Skip to content
Tools
Tools

Open-angle glaucoma

Drug research and approvals for open-angle glaucoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 83 studies of open-angle glaucoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 8 authorised medicines for it.

  • Recruiting worldwide: 83
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 8

Recruiting Now

Newest start dates first, of 83 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

16 approved, 4 in phase 3, 7 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Latanoprost, Timolol, Travoprost, Bimatoprost, Brimonidine, Brinzolamide, Dorzolamide, Tafluprost, Pilocarpine, Methazolamide, Betaxolol, Latanoprostene bunod, Netarsudil, Dapiprazole, Carteolol, Omidenepag isopropyl

Trabodenoson
Phase 3 Adenosine A1 receptor agonist
Memantine
Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
Ofloxacin
Phase 3 Bacterial DNA gyrase inhibitor
Citicoline
Phase 3
DE-104
Phase 2 Rho-associated protein kinase inhibitor
Anecortave acetate
Phase 2 Unknown
Mitomycin
Phase 2 DNA inhibitor
Ginkgo
Phase 2
Pyruvate
Phase 2
Ranibizumab
Phase 1 Vascular endothelial growth factor A inhibitor
Evodenoson
Phase 1 Adenosine A2a receptor agonist

How Its Trials Ended

860 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 195 whose ending is known, 53% met their primary endpoint, 1% missed it and 46% stopped early.

  • Completed, result not reported45853%
  • Ongoing10612%
  • Met its primary endpoint10412%
  • Status unknown10112%
  • Stopped: other or unclear516%
  • Stopped: enrollment or feasibility182%
  • Stopped: sponsor or business decision162%
  • Missed its primary endpoint20%
  • Stopped: lack of efficacy20%
  • Stopped: safety10%
  • Stopped: funding10%

Medicines Authorised in the EU

Newest first
Jan 7, 2021RoclandaLatanoprost / netarsudilSanten OyEMA ↗
Nov 19, 2019RhokiinsaNetarsudilSanten OyEMA ↗
Jul 18, 2014SimbrinzaBrinzolamide;brimonidine tartrateNovartis Europharm LimitedEMA ↗
Feb 20, 2014IzbaTravoprostNovartis Europharm LimitedEMA ↗
May 19, 2006GanfortBimatoprost;timololAbbVie Deutschland GmbH & Co. KGEMA ↗
Apr 23, 2006DuoTravTravoprost;timololNovartis Europharm LimitedEMA ↗
Mar 8, 2002LumiganBimatoprostAbbVie Deutschland GmbH & Co. KGEMA ↗
Nov 27, 2001TravatanTravoprostNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.